Emerging functional microfluidic assays for the study of thromboinflammation in sickle cell disease.
Emerging functional microfluidic assays for the study of thromboinflammation in sickle cell disease.
复制标题
DOI：
10.1097/moh.0000000000000731
复制
发表时间：
2022-11-01
影响因子：
3.2
通讯作者：
Gurkan, Umut A.
中科院分区：
文献类型：
--
作者：
An, Ran;Gurkan, Umut A.
关键词：
这篇综述简要总结了镰状细胞病血栓炎症的重要影响，与功能性微流控检测中使用的生物标志物的最新进展有关。镰状细胞病（SCD）是一种遗传性血红蛋白病，影响10万美国人和全世界数百万人。SCD患者表现出慢性溶血、慢性炎症和血栓形成以及血管闭塞，从而引发各种临床并发症，包括器官损伤以及死亡率和发病率增加。功能性微流体测定的最新进展提供了疾病的直接生物标志物，包括异常白色血细胞和红血细胞粘附、细胞聚集、内皮降解和收缩以及血栓形成。新型和新兴的功能性微流控检测是一种有前途和可行的策略，以全面表征SCD中的血栓炎症反应，可用于个性化的风险评估和定制的治疗决策。
This review briefly summarizes the significant impact of thromboinflammation in sickle cell disease in relation to recent advances in biomarkers that are used in functional microfluidic assays. Sickle cell disease (SCD) is an inherited hemoglobinopathy that affects 100 000 Americans and millions worldwide. Patients with SCD exhibit chronic haemolysis, chronic inflammation and thrombosis, and vaso-occlusion, triggering various clinical complications, including organ damage and increased mortality and morbidity. Recent advances in functional microfluidic assays provide direct biomarkers of disease, including abnormal white blood cell and red blood cell adhesion, cell aggregation, endothelial degradation and contraction, and thrombus formation. Novel and emerging functional microfluidic assays are a promising and feasible strategy to comprehensively characterize thromboinflammatory reactions in SCD, which can be used for personalized risk assessment and tailored therapeutic decisions.